Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a ret...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | JHLT Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133425000503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850144450600239104 |
|---|---|
| author | Lisa M. Raven, MBBS, FRACP Jerry R. Greenfield, MBBS (Hons 1), PhD, FRACP Andrew Jabbour, BSc (Med), MBBS (Hons), PhD, FRACP Peter S. Macdonald, MBBS, MD, PhD, FRACP Christopher A. Muir, MBBS (Hons), FRACP, PhD |
| author_facet | Lisa M. Raven, MBBS, FRACP Jerry R. Greenfield, MBBS (Hons 1), PhD, FRACP Andrew Jabbour, BSc (Med), MBBS (Hons), PhD, FRACP Peter S. Macdonald, MBBS, MD, PhD, FRACP Christopher A. Muir, MBBS (Hons), FRACP, PhD |
| author_sort | Lisa M. Raven, MBBS, FRACP |
| collection | DOAJ |
| description | Sodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m2 (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m2 (IQR −27 to +1) in patients not exposed to SGLT2i (p = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, p = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required. |
| format | Article |
| id | doaj-art-9c0270afdc4a40f58f138cb047dbf5bf |
| institution | OA Journals |
| issn | 2950-1334 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHLT Open |
| spelling | doaj-art-9c0270afdc4a40f58f138cb047dbf5bf2025-08-20T02:28:22ZengElsevierJHLT Open2950-13342025-05-01810025510.1016/j.jhlto.2025.100255Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantationLisa M. Raven, MBBS, FRACP0Jerry R. Greenfield, MBBS (Hons 1), PhD, FRACP1Andrew Jabbour, BSc (Med), MBBS (Hons), PhD, FRACP2Peter S. Macdonald, MBBS, MD, PhD, FRACP3Christopher A. Muir, MBBS (Hons), FRACP, PhD4Department of Diabetes and Endocrinology, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, Australia; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, Australia; School of Clinical Medicine, St Vincent’s Campus, Faculty of Medicine and Health, University of New South Wales, 390 Victoria Street, Darlinghurst, Sydney, Australia; Corresponding author: Lisa M. Raven, MBBS, FRACP, Department of Diabetes and Endocrinology, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, Australia.Department of Diabetes and Endocrinology, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, Australia; Clinical Diabetes, Appetite and Metabolism Laboratory, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, Australia; School of Clinical Medicine, St Vincent’s Campus, Faculty of Medicine and Health, University of New South Wales, 390 Victoria Street, Darlinghurst, Sydney, AustraliaSchool of Clinical Medicine, St Vincent’s Campus, Faculty of Medicine and Health, University of New South Wales, 390 Victoria Street, Darlinghurst, Sydney, Australia; Victor Chang Cardiac Research Institute, 405 Liverpool Street, Darlinghurst, Sydney, Australia; Department of Heart and Lung Transplantation, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, AustraliaSchool of Clinical Medicine, St Vincent’s Campus, Faculty of Medicine and Health, University of New South Wales, 390 Victoria Street, Darlinghurst, Sydney, Australia; Victor Chang Cardiac Research Institute, 405 Liverpool Street, Darlinghurst, Sydney, Australia; Department of Heart and Lung Transplantation, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, AustraliaDepartment of Diabetes and Endocrinology, St Vincent’s Hospital, 390 Victoria Street, Darlinghurst, Sydney, Australia; School of Clinical Medicine, St Vincent’s Campus, Faculty of Medicine and Health, University of New South Wales, 390 Victoria Street, Darlinghurst, Sydney, AustraliaSodium glucose cotransporter 2 inhibitors (SGLT2i) are standard of care for type 2 diabetes mellitus, heart failure, and chronic kidney disease (CKD). Heart transplant (HTx) recipients are at increased risk of diabetes and CKD, and both are independently associated with increased mortality. In a retrospective analysis of 104 HTx recipients with diabetes (23 exposed to SGLT2i, 81 not exposed), SGLT2i treatment was associated with stable renal function at 3 years post-HTx, measured by estimated glomerular filtration rate change from baseline (median change of 0 ml/min/1.73 m2 (interquartile range [IQR] −13 to +11)), compared to a change of −15 ml/min/1.73 m2 (IQR −27 to +1) in patients not exposed to SGLT2i (p = 0.02). There was no significant difference in survival by SGLT2i exposure, adjusted for diabetes type and baseline creatinine (hazard ratio 0.34, confidence intervals 0.11-1.06, p = 0.06). Further investigation of SGLT2i in HTx recipients, particularly focusing on renal outcomes, is required.http://www.sciencedirect.com/science/article/pii/S2950133425000503SGLT2sodium glucose cotransporter 2heart transplanttransplantationkidneyrenal |
| spellingShingle | Lisa M. Raven, MBBS, FRACP Jerry R. Greenfield, MBBS (Hons 1), PhD, FRACP Andrew Jabbour, BSc (Med), MBBS (Hons), PhD, FRACP Peter S. Macdonald, MBBS, MD, PhD, FRACP Christopher A. Muir, MBBS (Hons), FRACP, PhD Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation JHLT Open SGLT2 sodium glucose cotransporter 2 heart transplant transplantation kidney renal |
| title | Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| title_full | Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| title_fullStr | Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| title_full_unstemmed | Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| title_short | Sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| title_sort | sodium glucose cotransporter 2 inhibitors are associated with renal stabilization in heart transplantation |
| topic | SGLT2 sodium glucose cotransporter 2 heart transplant transplantation kidney renal |
| url | http://www.sciencedirect.com/science/article/pii/S2950133425000503 |
| work_keys_str_mv | AT lisamravenmbbsfracp sodiumglucosecotransporter2inhibitorsareassociatedwithrenalstabilizationinhearttransplantation AT jerryrgreenfieldmbbshons1phdfracp sodiumglucosecotransporter2inhibitorsareassociatedwithrenalstabilizationinhearttransplantation AT andrewjabbourbscmedmbbshonsphdfracp sodiumglucosecotransporter2inhibitorsareassociatedwithrenalstabilizationinhearttransplantation AT petersmacdonaldmbbsmdphdfracp sodiumglucosecotransporter2inhibitorsareassociatedwithrenalstabilizationinhearttransplantation AT christopheramuirmbbshonsfracpphd sodiumglucosecotransporter2inhibitorsareassociatedwithrenalstabilizationinhearttransplantation |